Nebenwirkungsmanagement in der Gynäkoonkologie

Immer mehr onkologische Erkrankungen werden durch Medikamente in oraler, subkutaner oder intramuskulärer Anwendungsform behandelt. Die selbstständige Einnahme bei oraler Applikation ist meist mit weniger Arztbesuchen, jedoch mit einer höheren Eigenverantwortung verbunden. Ein adäquates Nebenwirkungsmanagement auch für die Anwendung für zu Hause ist unumgänglich.

Schlüsselwörter

Mammakarzinom - CDK-4/6-Inhibitoren - orale Tumortherapie

• Literatur

• 1 Henze F, Bornemann K, Haupt J. et al. Interprofessionelles Management der oralen Tumortherapie. Im Fokus Onkologie 2023; 26: 18-23
• 2 O’Malley DM, Krivak TC, Kabil N. et al. PARP Inhibitors in Ovarian Cancer: A Review. Target Oncol 2023; 18: 471-503
• 3 Müller V, Welslau M, Lüftner D. et al. Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 590-600
• 4 Braal CL, Jongbloed EM, Wilting SM. et al. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib and Abemaciclib: Similarities and Differences. Drugs 2021; 81: 317-331
• 5 Miglietta F, Bottosso M, Griguolo G. et al. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open 2022; 7: 100409
• 6 Spring LM, Zangardi ML, Moy B. et al. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist 2017; 22: 1039-1048
• 7 Rugo HS, Brufsky A, Liu X. et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer. NPJ Breast Cancer 2022; 8: 114
• 8 Hartkopf AD, Fehm TM, Weslau M. et al. Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer. Geburtshilfe Frauenheilkd 2023; 83: 653-663
• 9 Thill M, Huober J, García-Sáenz JA. et al. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26: e53-e65
• 10 Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 2018; 10: 1758835918793326
• 11 Burris HA, Chan A, Bardia A. et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive HER2-negative advanced breast cancer. Br J Cancer 2021; 125: 679-686
• 12 Akbarali HI, Muchhala KH, Jessup DK. et al. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res 2022; 155: 131-166
• 13 Kornblau S, Benson AB, Catalano R. et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 2000; 19: 118-129
• 14 Ettl J. Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors. Breast Care (Basel) 2019; 14: 86-92
• 15 Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634
• 16 Carson JL, Strair R. Transfusion strategies in hematologic and nonhematologic disease. Hematology Am Soc Hematol Educ Program 2014; 2014: 548-552
• 17 Schlam I, Giordano A, Tolaney SM. Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer. Expert Opin Drug Saf 2023; 22: 1149-1156
• 18 Novartis Pharma. Fachinformation Kisqali 200 mg Filmtabletten. Accessed August 19, 2024 at: https://www.novartis.com/at-de/sites/novartis_at/files/FI_Kisqali_FTA.pdf
• 19 Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Ann Dermatol Venereol 2023; 150: 208-212
• 20 Stone P, Candelmi DE, Kandola K. et al. Management of Fatigue in Patients with Advanced Cancer. Curr Treat Options Oncol 2023; 24: 93-107
• 21 West MT, Smith CE, Kaempf A. et al. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol 2021; 106: 634-642